- Home
- ZYBT vs CANF Comparison
ZYBT vs CANF Comparison
Compare ZYBT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYBT
- CANF
- Stock Information
- Founded
- ZYBT 2004
- CANF 1994
- Country
- ZYBT China
- CANF Israel
- Employees
- ZYBT N/A
- CANF N/A
- Industry
- ZYBT
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- ZYBT
- CANF Health Care
- Exchange
- ZYBT NYSE
- CANF Nasdaq
- Market Cap
- ZYBT N/A
- CANF 7.9M
- IPO Year
- ZYBT 2025
- CANF N/A
- Fundamental
- Price
- ZYBT $9.01
- CANF $1.19
- Analyst Decision
- ZYBT
- CANF Strong Buy
- Analyst Count
- ZYBT 0
- CANF 2
- Target Price
- ZYBT N/A
- CANF $14.00
- AVG Volume (30 Days)
- ZYBT 605.7K
- CANF 400.8K
- Earning Date
- ZYBT 01-01-0001
- CANF 05-06-2025
- Dividend Yield
- ZYBT N/A
- CANF N/A
- EPS Growth
- ZYBT N/A
- CANF N/A
- EPS
- ZYBT 0.06
- CANF N/A
- Revenue
- ZYBT $26,111,272.00
- CANF $674,000.00
- Revenue This Year
- ZYBT N/A
- CANF $461.72
- Revenue Next Year
- ZYBT N/A
- CANF N/A
- P/E Ratio
- ZYBT $125.96
- CANF N/A
- Revenue Growth
- ZYBT N/A
- CANF N/A
- 52 Week Low
- ZYBT $3.50
- CANF $1.22
- 52 Week High
- ZYBT $11.20
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- ZYBT N/A
- CANF 38.82
- Support Level
- ZYBT N/A
- CANF $1.22
- Resistance Level
- ZYBT N/A
- CANF $1.27
- Average True Range (ATR)
- ZYBT 0.00
- CANF 0.13
- MACD
- ZYBT 0.00
- CANF -0.02
- Stochastic Oscillator
- ZYBT 0.00
- CANF 6.41
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).